Nano-Medicine: Revolutionizing Therapeutics, Diagnostics, and Regeneration

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Nanomedicine and Nanobiology".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 858

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
Interests: nanoparticles; primary cells; endothelial cells; blood; platelets

Special Issue Information

Dear Colleagues,

Nanotechnology has emerged as a game-changer in medicine, offering inventive solutions across therapeutics, diagnostics, and tissue regeneration. This field involves manipulating materials at the nanoscale, granting precise control over their characteristics and behavior.

In therapeutics, nanotechnology has transformed drug delivery. Nanoparticles can encase therapeutic agents and be tailored to target specific cells or tissues, boosting drug effectiveness while minimizing side effects. They also serve as carriers for controlled drug release, bolstering drug stability and availability.

Nanoparticles can be modified with specific elements to detect disease biomarkers, enhancing imaging techniques like MRI, CT scans, and fluorescence imaging. Nanotech-based diagnostics offer better sensitivity and early disease detection potential.

Additionally, nanotechnology aids tissue regeneration by providing scaffolds and hydrogels that support cell growth and mimic natural tissues. These materials promote cell adhesion and growth, with controlled release of growth factors aiding tissue repair.

By merging nanotechnology and medicine, we're exploring new avenues for targeted therapies, early detection, and improved tissue regeneration. This special issue showcases various studies and reviews highlighting nanotechnology's diverse applications in medicine, spanning therapeutics, diagnostics, and tissue regeneration.

Dr. Sonali Suresh Rohiwal
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery systems
  • targeted therapies
  • disease detection
  • tissue regeneration
  • regenerative medicine
  • nanomaterials

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 8132 KiB  
Article
Rational Design of Pectin–Chitosan Polyelectrolyte Nanoparticles for Enhanced Temozolomide Delivery in Brain Tumor Therapy
by Vladimir E. Silant’ev, Andrei S. Belousov, Fedor O. Trukhin, Nadezhda E. Struppul, Mikhail E. Shmelev, Aleksandra A. Patlay, Roman A. Shatilov and Vadim V. Kumeiko
Biomedicines 2024, 12(7), 1393; https://doi.org/10.3390/biomedicines12071393 - 23 Jun 2024
Viewed by 613
Abstract
Conventional chemotherapeutic approaches currently used for brain tumor treatment have low efficiency in targeted drug delivery and often have non-target toxicity. Development of stable and effective drug delivery vehicles for the most incurable diseases is one of the urgent biomedical challenges. We have [...] Read more.
Conventional chemotherapeutic approaches currently used for brain tumor treatment have low efficiency in targeted drug delivery and often have non-target toxicity. Development of stable and effective drug delivery vehicles for the most incurable diseases is one of the urgent biomedical challenges. We have developed polymer nanoparticles (NPs) with improved temozolomide (TMZ) delivery for promising brain tumor therapy, performing a rational design of polyelectrolyte complexes of oppositely charged polysaccharides of cationic chitosan and anionic pectin. The NPs’ diameter (30 to 330 nm) and zeta-potential (−29 to 73 mV) varied according to the initial mass ratios of the biopolymers. The evaluation of nanomechanical parameters of native NPs demonstrated changes in Young’s modulus from 58 to 234 kPa and adhesion from −0.3 to −3.57 pN. Possible mechanisms of NPs’ formation preliminary based on ionic interactions between ionogenic functional groups were proposed by IR spectroscopy and dynamic rheology. The study of the parameters and kinetics of TMZ sorption made it possible to identify compounds that most effectively immobilize and release the active substance in model liquids that simulate the internal environment of the body. A polyelectrolyte carrier based on an equal ratio of pectin–chitosan (0.1% by weight) was selected as the most effective for the delivery of TMZ among a series of obtained NPs, which indicates a promising approach to the treatment of brain tumors. Full article
Show Figures

Figure 1

Back to TopTop